文献速递浆细胞疾病

前沿基因组学揭示多发性骨髓瘤肿瘤发生、疾病进展及治疗影响的新见解

Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-05-03

本文综述多发性骨髓瘤(MM)的基因组学进展,讨论线性、扩张型和克隆内异质性三种演化模型,重点阐述克隆内异质性模型中驱动突变与乘客突变的选择压力,以及临床干预对亚克隆存活和治疗耐药的影响,并介绍二代测序在揭示MM发生、进展和治疗中的关键作用。

要点

  • MM几乎均继发于意义未明的单克隆丙种球蛋白病(MGUS),其转化涉及复杂遗传改变。
  • 克隆内异质性模型中,不同MM浆细胞群体携带不同突变组合,驱动突变影响选择压力和优势。
  • 临床干预对肿瘤细胞施加额外选择压力,可影响亚克隆存活并导致治疗耐药。

核心结论

  • MM仍基本不可治愈,中位生存期为6年,理解MGUS向MM转化的遗传改变可提供临床干预靶点。
  • 二代测序方法正在揭示MM发生、疾病进展和治疗的关键遗传学见解,MM疾病进展将阐明肿瘤的潜在机制。

研究设计与样本

  • 综述,讨论MM演化的三种模型:线性模型、扩张型模型和克隆内异质性模型。

主要发现

  • 几乎所有MM病例发生前均存在良性浆细胞疾病MGUS,MGUS向MM的转化与复杂遗传改变相关。
  • 克隆内异质性模型中,不同MM浆细胞群体携带不同遗传突变组合,获得额外突变可促成亚克隆谱系。
  • 驱动突变可能影响选择压力和优势,而乘客突变效应中性。
  • 临床干预对肿瘤细胞引入额外选择压力,可影响亚克隆存活,导致治疗耐药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal expansion of plasma cells (PCs) within the bone marrow. Despite advances in therapy, MM remains a largely incurable disease with a median survival of 6 years. In almost all cases, the development of MM is preceded by the benign PC condition Monoclonal Gammopathy of Undetermined Significance (MGUS). Recent studies show that the transformation of MGUS to MM is associated with complex genetic changes. Understanding how these changes contribute to evolution will present targets for clinical intervention. We discuss three models of MM evolution; the linear, the expansionist and the intraclonal heterogeneity models. Of particular interest is the intraclonal heterogeneity model. Here, distinct populations of MM PCs carry differing combinations of genetic mutations. Acquisition of additional mutations can contribute to subclonal lineages where "driver" mutations may influence selective pressure and dominance, and "passenger" mutations are neutral in their effects. Furthermore, studies show that clinical intervention introduces additional selective pressure on tumour cells and can influence subclone survival, leading to therapy resistance. This review discusses how Next Generation Sequencing approaches are revealing critical insights into the genetics of MM development, disease progression and treatment. MM disease progression will illuminate possible mechanisms underlying the tumour.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dutta AK, Hewett DR, Fink JL, et al. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. Br J Haematol. 2017. PMID: 28466550. doi:10.1111/bjh.14649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。